275 related articles for article (PubMed ID: 23955900)
1. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
[TBL] [Abstract][Full Text] [Related]
2. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.
Walter RB; Pagel JM; Gooley TA; Petersdorf EW; Sorror ML; Woolfrey AE; Hansen JA; Salter AI; Lansverk E; Stewart FM; O'Donnell PV; Appelbaum FR
Leukemia; 2010 Jul; 24(7):1276-82. PubMed ID: 20485378
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
5. Superior transplantation outcomes of 8/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission.
Cho BS; Kim JH; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Eur J Haematol; 2013 May; 90(5):365-74. PubMed ID: 23414524
[TBL] [Abstract][Full Text] [Related]
6. Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics.
Park EG; Yi ES; Choi YB; Sung KW; Koo HH; Yoo KH
Pediatr Transplant; 2019 Jun; 23(4):e13397. PubMed ID: 30955250
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
Ustun C; Giannotti F; Zhang MJ; Wang HL; Brunstein C; Labopin M; Rocha V; de Lima M; Baron F; Sandmaier BM; Eapen M; Gluckman E; Nagler A; Weisdorf DJ; Ruggeri A
Leukemia; 2017 Jun; 31(6):1408-1414. PubMed ID: 28119528
[TBL] [Abstract][Full Text] [Related]
8. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
Gupta V; Tallman MS; He W; Logan BR; Copelan E; Gale RP; Khoury HJ; Klumpp T; Koreth J; Lazarus HM; Marks DI; Martino R; Rizzieri DA; Rowe JM; Sabloff M; Waller EK; DiPersio JF; Bunjes DW; Weisdorf DJ
Blood; 2010 Sep; 116(11):1839-48. PubMed ID: 20538804
[TBL] [Abstract][Full Text] [Related]
9. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
Foran JM; Pavletic SZ; Logan BR; Agovi-Johnson MA; Pérez WS; Bolwell BJ; Bornhäuser M; Bredeson CN; Cairo MS; Camitta BM; Copelan EA; Dehn J; Gale RP; George B; Gupta V; Hale GA; Lazarus HM; Litzow MR; Maharaj D; Marks DI; Martino R; Maziarz RT; Rowe JM; Rowlings PA; Savani BN; Savoie ML; Szer J; Waller EK; Wiernik PH; Weisdorf DJ
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1102-8. PubMed ID: 23632091
[TBL] [Abstract][Full Text] [Related]
10. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
11. Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.
Rodríguez-Arbolí E; Márquez-Malaver FJ; Rodríguez-Torres N; Caballero-Velázquez T; Escamilla-Gómez V; Calderón-Cabrera C; Falantes-González JF; Solé-Rodríguez M; García-Ramírez P; Moya-Arnao M; Carreras E; Espigado-Tocino I; Pérez-Simón JA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):183-190. PubMed ID: 30153492
[TBL] [Abstract][Full Text] [Related]
12. [Autologous versus unrelated donor stem cell transplantation for adults with primary acute myeloid leukemia in first remission].
Yao JF; Zhang GX; Yang DL; He Y; Wei JL; Zhai WH; Jiang EL; Zhang RL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):365-372. PubMed ID: 32536132
[No Abstract] [Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.
Burke MJ; Wagner JE; Cao Q; Ustun C; Verneris MR
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1021-5. PubMed ID: 23567175
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.
Adrianzen Herrera D; Kornblum N; Derman O; Bachier-Rodriguez L; Sica RA; Shastri A; Janakiram M; Verma A; Braunschweig I; Mantzaris I
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):516-521. PubMed ID: 31227357
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.
Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Oncotarget; 2017 Jun; 8(25):41590-41604. PubMed ID: 28206975
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
[TBL] [Abstract][Full Text] [Related]
17. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.
Kumar P; Defor TE; Brunstein C; Barker JN; Wagner JE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1394-400. PubMed ID: 19041062
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
20. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
Lorentino F; Labopin M; Bernardi M; Ciceri F; Socié G; Cornelissen JJ; Esteve J; Ruggeri A; Volin L; Yacoub-Agha I; Craddock C; Passweg J; Blaise D; Gedde-Dahl T; Poiani M; Fegueux N; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1236-1244. PubMed ID: 30058714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
